



T2 Biosystems®

Distributed by



T2 Biosystems

T2Dx® Diagnostics

SAME DAY targeted therapy starts in the lab

Testing with the T2Dx Diagnostics

Identify the major pathogens that cause sepsis **without waiting for blood culture**. Detect within 6 hours of blood sample receipt to help physicians:

- Get species ID faster than ever before
- Get patients on the right therapy faster
- Improve morbidity and mortality outcomes
- Improve antimicrobial stewardship
- Consider de-escalation of antimicrobials before blood culture results are available
- Reduce the costs of sepsis management

T2Dx Instrument

- Direct from whole blood
- Results in 3 to 5 hours
- As low as 1 CFU/mL LoD
- Easy to operate
- Cartridge-based



T2Dx panels identify the most **deadly and prevalent species** that are not often covered by broad-spectrum therapy.

T2Bacteria® Panel*

95.8% Sensitivity | 98.1% Specificity¹

- *Enterococcus faecium*
- *Staphylococcus aureus*
- *Klebsiella pneumoniae*
- *Acinetobacter baumannii*
- *Pseudomonas aeruginosa*
- *Escherichia coli*

T2Candida® Panel

91.1% Sensitivity | 99.4% Specificity²

- *Candida albicans*
- *Candida tropicalis*
- *Candida krusei*
- *Candida glabrata*
- *Candida parapsilosis*

T2Dx Diagnostics


Early targeted therapy faster than ever



Breakthrough technology enabling direct detection from whole blood

The T2Dx Instrument is an easy to use, fully-automated, random access benchtop diagnostic system that enhances sepsis management with rapid, actionable species identification. Busy lab technicians can count on T2Dx diagnostics to deliver a consistent, high quality result.

Redefining rapid diagnostics



To learn more about the T2Dx diagnostics, email

info@t2biosystems.com or visit www.t2biosystems.com

Distributed by



Deliver exceptional patient care

Sepsis is managed through rapid interventions, including prompt administration of broad-spectrum empiric therapy. While waiting days for blood culture results, initial empiric therapy is often changed multiple times in an effort to get patients on the right therapy as fast as possible. By screening suspected patients at the first sign of sepsis, physicians can get their patients on targeted therapy far faster and increase the odds of both survival and a rapid recovery.

T2Dx Instrument

- Fully-automated benchtop design
- Random access workflow
- "Sample in — results out" processing
- Minimal specimen handling
- LoD as low as 1 CFU/mL
- Cartridge-based

1. T2Bacteria Pivotal Study data presented by Leber Podium Presentation IDWeek 2017.

2. Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, L., Garey, et al. (2015). T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. *Clinical infectious diseases*, ciu959.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, T2Dx®, and the T2 Biosystems, Inc. logo are registered trademarks of T2 Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. ©2018 T2 Biosystems. All rights reserved. T2_717 R02 0318

